28
Participants
Start Date
April 1, 2022
Primary Completion Date
December 1, 2025
Study Completion Date
December 1, 2025
Venetoclax, Azacitidine
Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
RECRUITING
The First Affliated Hospital of Soochow University, Suzhou
Jining Medical University
OTHER
The Second People's Hospital of Huai'an
OTHER
The First Affiliated Hospital of Bengbu Medical University
OTHER
Northern Jiangsu People's Hospital
OTHER
Affiliated Hospital of Nantong University
OTHER
Suzhou Hospital of Traditional Chinese Medicine
OTHER
The First Affiliated Hospital of Soochow University
OTHER